[en] During the first year of funding, C-11 hydroxyephedrine has been introduced as the first clinically usable norepinephrine analogue. Studies in normal volunteers and patients with various cardiac disorders indicated the feasibility of this tracer for further evaluation. Simultaneously, animal studies have been used to assess the use of these radiopharmaceuticals in ischemic injury in order to define neuronal damage. Current research focuses on the comparison of C-11 hydroxyephedrine with other neurotransmitters such as C-11 epinephrine and C-11 threo-hydroxyephedrine. Epinephrine is primarily stored in vesicles of the nerve terminal, while threo-hydroxyephedrine is only substrate to uptake I mechanism. Such a combination of radiotracers may allow the dissection of uptake I mechanism as well as vesicular storage. In parallel to the refinement of presynaptic tracers for the sympathetic nervous system, the authors are developing radiopharmaceuticals to delineate the adrenergic receptors in the heart. The combined evaluation of pre- and postsynaptic nerve function will improve their ability to identify abnormalities. They are currently developing a new radiosynthesis of the hydrophilic adrenergic receptor antagonist C-11 CGP-12177 which has been used by others for the visualization of adrenergic receptors in the heart. In addition, they are participating in the development of radiopharmaceuticals for the delineation of presynaptic cholinergic nerve terminals. Derivatives of benzovesamicol have been labeled in their institution and are currently under investigation. The most promising agent is F-18 benzovesamicol (FEBOBV) which allows the visualization of parasympathetic nerve terminals in the canine heart as demonstrated by preliminary PET data. A compilation of all publications funded by this grant is presented in this report